SYSTEMIC INTERLEUKIN 1β INHIBITION IN PROLIFERATIVE DIABETIC RETINOPATHY: A Prospective Open-Label Study Using Canakinumab

PURPOSE: To evaluate the effect of systemic interleukin 1β inhibition using canakinumab (Ilaris) on retinal neovascularizations in proliferative diabetic retinopathy. METHODS: Patients with proliferative diabetic retinopathy were enrolled in a prospective uncontrolled pilot study. Canakinumab (150 m...

Descripción completa

Detalles Bibliográficos
Autores principales: Stahel, Marc, Becker, Matthias, Graf, Nicole, Michels, Stephan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Retina 2016
Materias:
Original Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747976/
https://www.ncbi.nlm.nih.gov/pubmed/26218500
http://dx.doi.org/10.1097/IAE.0000000000000701

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4747976/
https://www.ncbi.nlm.nih.gov/pubmed/26218500
http://dx.doi.org/10.1097/IAE.0000000000000701

Ejemplares similares